AbbVie Inc. closed 15.11% below its 52-week high of $218.66, which the company achieved on March 10th.

AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track ...

India's Glenmark Pharmaceuticals said on Thursday its innovation arm, Ichnos Glenmark Innovation (IGI), and AbbVie have ...

AbbVie Inc. (NYSE:ABBV) is one of the best stocks for a dividend stock portfolio. The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed ...

Shares of AbbVie Inc. ABBV slipped 2.40% to $182.31 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.52% to 6,173.07 ...

AbbVie Inc. (NYSE: ABBV) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, the “Elahere Market Opportunities and Strategies to 2034” report was added to ...

The company announced that the US FDA has expanded the approved use of its oral antiviral drug Mavyret, developed in partnership with Enanta Pharmaceuticals, Inc.

Glenmark Pharmaceuticals shares rallied 10% on Friday to reach a record high after its biotech subsidiary signed a ...

(RTTNews) - Biopharmaceutical company AbbVie, Inc. (ABBV) announced Wednesday positive topline results from its Phase 3 TEMPLE multicenter, randomized, double-blind, head-to-head study evaluating ...

NORTH CHICAGO - AbbVie Inc. (NYSE: ABBV), a pharmaceutical giant with a market capitalization of $327.65 billion, announced Friday that its board of directors has declared a quarterly cash dividend of ...

AbbVie said on Wednesday its migraine drug met the main goal and was superior to a widely used generic treatment in a head-to head late-stage trial.